<DOC>
	<DOCNO>NCT00034840</DOCNO>
	<brief_summary>The primary objective demonstrate MICARDIS® ( telmisartan ) statistically superior Diovan® ( valsartan ) reduce diastolic blood pressure ( DBP ) follow miss dose end 6 8-week treatment period measure 24-hour ABPM mean demonstrate MICARDIS® statistically superior Diovan® reduce DBP last 6-hours 24-hour dosing interval measure ABPM follow dose active study medication end 6 8-week treatment period .</brief_summary>
	<brief_title>Telmisartan vs. Valsartan Patients With Mild Moderate Hypertension Following Missed Dose</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>1 . Mildtomoderate hypertension define baseline mean seat DBP great equal 95 mm Hg le equal 109 mm Hg baseline 24hour ABPM mean DBP great equal 85 mm Hg . 1 . Premenopausal woman ( last menstruation = 1 year prior sign informed consent ) : Are surgically sterile . Are nurse . Are childbearing potential NOT practice acceptable method birth control , NOT plan continue practice acceptable method throughout study . Acceptable method birth control include IUD , oral , implantable injectable contraceptive . No exception make . 2 . Night shift worker routinely sleep daytime whose work hour include midnight 4:00 A.M. 3 . Mean sit SBP =180 mm Hg mean sit DBP =110 mm Hg visit placebo runin period . 4 . Known suspected secondary hypertension ( i.e. , pheochromocytoma ) . 5 . Hepatic and/or renal dysfunction define follow laboratory parameter : SGPT ( ALT ) SGOT ( AST ) &gt; 2 time upper limit normal range . Serum creatinine &gt; 2.3 mg/dL ( &gt; 203 µmol/l ) . 6 . Bilateral renal artery stenosis , renal artery stenosis solitary kidney , postrenal transplant patient patient one kidney . 7 . Clinically relevant sodium depletion , hypokalaemia hyperkalaemia . 8 . Uncorrected volume depletion . 9 . Primary aldosteronism . 10 . Hereditary fructose intolerance . 11 . Biliary obstructive disorder . 12 . Congestive heart failure ( NYHA functional class CHF IIIIV ) . 13 . Unstable angina within past three month prior sign inform consent form . 14 . Stroke within past six month prior sign inform consent form . 15 . Myocardial infarction cardiac surgery within past three month prior sign inform consent form . 16 . PTCA ( percutaneous transluminal coronary revascularization ) within past three month prior sign inform consent form . 17 . Sustained ventricular tachycardia , atrial fibrillation , atrial flutter clinically relevant cardiac arrhythmia determine investigator . 18 . Hypertrophic obstructive cardiomyopathy , aortic stenosis , hemodynamically relevant stenosis aortic mitral valve . 19 . Patients insulindependent diabetes mellitus whose diabetes stable control least past three month define HbA1C =10 % . 20 . Patients previously experience symptom characteristic angioedema treatment ACE inhibitor angiotensin II receptor antagonist . 21 . History drug alcohol dependency within 6 month prior sign inform consent form . 22 . Chronic administration medication know affect blood pressure , except medication allow protocol . 23 . Any investigational therapy within one month signing informed consent form . 24 . Known hypersensitivity component formulation . 25 . Any clinical condition , opinion investigator would allow safe completion protocol safe administration trial medication . 26 . Inability comply protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>hypertension</keyword>
	<keyword>telmisartan</keyword>
	<keyword>valsartan</keyword>
	<keyword>boehringer</keyword>
</DOC>